Kyntra Bio
KYNB
207 hedge funds and large institutions have $2.67B invested in Kyntra Bio in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 70 reducing their positions, and 25 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
47% more call options, than puts
Call options by funds: $50.5M | Put options by funds: $34.4M
0.11% more ownership
Funds ownership: 3.05% → 3.16% (+0.11%)
0% less funds holding
Funds holding: 208 → 207 (-1)
3% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 70
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
6% less capital invested
Capital invested by funds: $2.84B → $2.67B (-$166M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$90.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16M |
| 3 |
BlackRock
New York
|
+$15.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 5 |
Morgan Stanley
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.5M |
| 2 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$14.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$10.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.98M |
KYNB Hedge Fund Activity: Q4 2020 in Review
207 of the 5,675 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2020, worth a combined $2.67B — down 5.9% from $2.84B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of KYNB and 24 opened new positions — a net loss of 1 holder — while 70 trimmed existing stakes and 68 added.
The largest buyer was Primecap Management, adding an estimated $90.1M. The largest seller was Fidelity Investments, cutting an estimated $29.5M.
- 207 institutional investors held Kyntra Bio (KYNB) as of Q4 2020, down from 208 in Q3 2020.
- Funds reported $2.67B of Kyntra Bio stock for Q4 2020, down 5.9% quarter-over-quarter.
- 24 funds opened new Kyntra Bio positions in Q4 2020 and 25 closed out, a net change of -1 holder.
- The largest Kyntra Bio buyer in Q4 2020 was Primecap Management, an estimated $90.1M added.
- The largest Kyntra Bio seller in Q4 2020 was Fidelity Investments, an estimated $29.5M sold.
Based on aggregated 13F filings for Q4 2020.